The Sputnik Light vaccine, which is the first component of Sputnik V, was 78.6% effective against laboratory-confirmed coronavirus infections. 87.6% for the reduction of hospitalizations and 84.8% in the prevention of deaths in a population aged 60 to 79 years, according to a study carried out in Argentina, published this Monday in the journal ClinicalMedicine.
The work consisted of a retrospective cohort study of 415,995 people in which individuals aged 60 to 79 years who self-enrolled in the online vaccination system of the province of Buenos Aires from December 29, 2020 to December 21, were analyzed. March 2021.
“The results of this study conducted in real-life settings indicate that the first component of the Gam-COVID-Vac (Sputnik V) vaccine prevents 78.6% of laboratory-confirmed SARS-CoV-2 infections, the 87.6% of hospitalizations and 84.8% of deaths between 21 and 83 days after vaccination in a population aged 60 to 79 years; these data are consistent with previous knowledge on the subject “, indicated the authors of the study .
However, they warned that, “without a doubt, the complete vaccination schedule should be the standard of care since it confers maximum effectiveness.”
The data was advanced before printing in this peer-reviewed journal on June 2 by the Ministry of Health of the province of Buenos Aires, who carried out the work together with the National Health Surveillance System and the Bed Management System. of the province of Buenos Aires.
Sputnik Light is the first component of the human adenovirus-based Sputnik V vaccine developed by Russia’s Gamaleya Research Center.